13-Mar-2026
Catalyst Watch: Nvidia's GTC Conference, FOMC meeting, Okta event, and triple-witching day
Seeking Alpha News (Fri, 13-Mar 3:00 PM ET)
Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early
Benzinga (Fri, 13-Mar 1:23 PM ET)
Dividend Roundup: Microsoft, Meta Platforms, Merck & Co., Target, and more
Seeking Alpha News (Fri, 13-Mar 8:41 AM ET)
Immutep halts late-stage trial for lead asset after efficacy analysis
Seeking Alpha News (Fri, 13-Mar 6:53 AM ET)
Merck & Company (MRK) Gets a Hold from Bernstein
TipRanks (Fri, 13-Mar 5:48 AM ET)
Barclays Keeps Their Buy Rating on Merck & Company (MRK)
TipRanks (Fri, 13-Mar 4:56 AM ET)
Eli Lilly tops growth factor grades among S&P healthcare holdings
Seeking Alpha News (Thu, 12-Mar 4:31 PM ET)
Codexis rises after Q4 beat, strong outlook
Seeking Alpha News (Thu, 12-Mar 7:39 AM ET)
IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors
TipRanks (Tue, 10-Mar 4:22 PM ET)
IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification
TipRanks (Tue, 10-Mar 4:22 PM ET)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Merck Common (New) trades on the NYSE stock market under the symbol MRK.
As of March 13, 2026, MRK stock price declined to $115.61 with 6,082,440 million shares trading.
MRK has a beta of 0.62, meaning it tends to be less sensitive to market movements. MRK has a correlation of 0.12 to the broad based SPY ETF.
MRK has a market cap of $285.83 billion. This is considered a Mega Cap stock.
Last quarter Merck Common (New) reported $16 billion in Revenue and $2.04 earnings per share. This beat revenue expectation by $200 million and exceeded earnings estimates by $.02.
In the last 3 years, MRK traded as high as $134.63 and as low as $73.31.
The top ETF exchange traded funds that MRK belongs to (by Net Assets): VTI, VOO, IVV, SCHD, SPY.
MRK has outperformed the market in the last year with a return of +25.5%, while the SPY ETF gained +21.4%. In the last 3 month period, MRK beat the market returning +17.1%, while SPY returned -2.6%. However, in the most recent 2 weeks MRK has underperformed the stock market by returning -6.6%, while SPY returned -3.5%.
MRK support price is $113.87 and resistance is $117.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRK shares will trade within this expected range on the day.